RE:Feb 27 mtglscfa wrote: Will any news be out before then? Will the Phase 3 results for macmorilen be released?
The current pediatric trial was expected to be fully enrolled by the end of 2023. Here's how long it took to announce prior results:
"On January 28, 2020, we announced the successful completion of patient recruitment for the first pediatric study of macimorelin as a growth hormone stimulation test for the evaluation of GHD in children." "The final study results from Study P01 were published in the second quarter of 2020 indicating positive safety and tolerability data for use of macimorelin in CGHD, as well as PK/PD data observed in a range as expected from the adult studies." The trial results, potential approval in 2024 and a new licensing deal should drive AEZS in 2024 as the product is also being tolled out in Europe and elsewhere for adults.